Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

View More View Less
  • 1 Robert H. Lurie Comprehensive Cancer Center of Northwestern University;
  • | 2 Yale Cancer Center/Smilow Cancer Hospital;
  • | 3 Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;
  • | 4 Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;
  • | 5 The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;
  • | 6 Stanford Cancer Institute;
  • | 7 University of Wisconsin Carbone Cancer Center;
  • | 8 Dana-Farber/Brigham and Women’s Cancer Center;
  • | 9 UC Davis Comprehensive Cancer Center;
  • | 10 Memorial Sloan Kettering Cancer Center;
  • | 11 University of Colorado Cancer Center;
  • | 12 The University of Texas MD Anderson Cancer Center;
  • | 13 Mayo Clinic Cancer Center;
  • | 14 Fox Chase Cancer Center;
  • | 15 UCLA Jonsson Comprehensive Cancer Center;
  • | 16 Massachusetts General Hospital Cancer Center;
  • | 17 Abramson Cancer Center at the University of Pennsylvania;
  • | 18 Fred Hutchinson Cancer Research Center/University of Washington;
  • | 19 Fred & Pamela Buffet Cancer Center;
  • | 20 UT Southwestern Simmons Comprehensive Cancer Center;
  • | 21 City of Hope National Medical Center;
  • | 22 University of Michigan Rogel Cancer Center;
  • | 23 Duke Cancer Institute;
  • | 24 UCSF Helen Diller Family Comprehensive Cancer Center;
  • | 25 UC San Diego Moores Cancer Center;
  • | 26 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;
  • | 27 Research Advocacy Network;
  • | 28 Moffitt Cancer Center;
  • | 29 O'Neal Comprehensive Cancer Center at UAB;
  • | 30 Huntsman Cancer Institute at the University of Utah;
  • | 31 Roswell Park Comprehensive Cancer Center; and
  • | 32 National Comprehensive Cancer Network.

The therapeutic options for patients with noninvasive or invasive breast cancer are complex and varied. These NCCN Clinical Practice Guidelines for Breast Cancer include recommendations for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget disease, phyllodes tumor, inflammatory breast cancer, and management of breast cancer during pregnancy. The content featured in this issue focuses on the recommendations for overall management of ductal carcinoma in situ and the workup and locoregional management of early stage invasive breast cancer. For the full version of the NCCN Guidelines for Breast Cancer, visit NCCN.org.

Individual Disclosures for the NCCN Breast Cancer Panel
Individual Disclosures for the NCCN Breast Cancer Panel

  • 1.

    Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin 2022;72:733.

  • 2.

    College of American Pathologist. College of American Pathologist protocols. Accessed April, 2022. Available at http://www.cap.org

  • 3.

    Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and progesterone receptor testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists guideline update. Arch Pathol Lab Med 2020;144:545563.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Kerlikowske K, Molinaro AM, Gauthier ML, et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 2010;102:627637.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Stackievicz R, Paran H, Bernheim J, et al. Prognostic significance of HER-2/neu expression in patients with ductal carcinoma in situ. Isr Med Assoc J 2010;12:290295.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Zhou W, Jirström K, Johansson C, et al. Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study. BMC Cancer 2010;10:653.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Lari SA, Kuerer HM. Biological markers in DCIS and risk of breast recurrence: a systematic review. J Cancer 2011;2:232261.

  • 8.

    Cobleigh MA, Anderson SJ, Siziopikou KP, et al. Comparison of radiation with or without concurrent trastuzumab for HER2-positive ductal carcinoma in situ resected by lumpectomy: a phase III clinical trial. J Clin Oncol 2021;39:23672374.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Kuhl CK, Schrading S, Bieling HB, et al. MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study. Lancet 2007;370:485492.

  • 10.

    Allen LR, Lago-Toro CE, Hughes JH, et al. Is there a role for MRI in the preoperative assessment of patients with DCIS? Ann Surg Oncol 2010;17:23952400.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Davis KL, Barth RJ Jr., Gui J, et al. Use of MRI in preoperative planning for women with newly diagnosed DCIS: risk or benefit? Ann Surg Oncol 2012;19:32703274.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Pilewskie M, Olcese C, Eaton A, et al. Perioperative breast MRI is not associated with lower locoregional recurrence rates in DCIS patients treated with or without radiation. Ann Surg Oncol 2014;21:15521560.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    Lam DL, Smith J, Partridge SC, et al. The impact of preoperative breast MRI on surgical management of women with newly diagnosed ductal carcinoma in situ. Acad Radiol 2020;27:478486.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Chou SS, Romanoff J, Lehman CD, et al. Preoperative breast MRI for newly diagnosed ductal carcinoma in situ: imaging features and performance in a multicenter setting (ECOG-ACRIN E4112 trial). Radiology 2021;301:6677.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15.

    Bijker N, Meijnen P, Peterse JL, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 2006;24:33813387.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Emdin SO, Granstrand B, Ringberg A, et al. SweDCIS: radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol 2006;45:536543.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17.

    Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998;16:441452.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Houghton J, George WD, Cuzick J, et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 2003;362:95102.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Julien JP, Bijker N, Fentiman IS, et al. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. Lancet 2000;355:528533.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Cuzick J, Sestak I, Pinder SE, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol 2011;12:2129.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Wapnir IL, Dignam JJ, Fisher B, et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 2011;103:478488.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    McCormick B, Winter K, Hudis C, et al. RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol 2015;33:709715.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Holmberg L, Garmo H, Granstrand B, et al. Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J Clin Oncol 2008;26:12471252.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Goodwin A, Parker S, Ghersi D, et al. Post-operative radiotherapy for ductal carcinoma in situ of the breast--a systematic review of the randomised trials. Breast 2009;18:143149.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Narod SA, Iqbal J, Giannakeas V, et al. Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol 2015;1:888896.

  • 26.

    Sagara Y, Freedman RA, Vaz-Luis I, et al. Patient prognostic score and associations with survival improvement offered by radiotherapy after breast-conserving surgery for ductal carcinoma in situ: a population-based longitudinal cohort study. J Clin Oncol 2016;34:11901196.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Giannakeas V, Sopik V, Narod SA. Association of radiotherapy with survival in women rreated for ductal carcinoma in situ with lumpectomy or mastectomy. JAMA Netw Open 2018;1:e181100.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 28.

    Bartelink H, Horiot JC, Poortmans PM, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 2007;25: 32593265.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Bartelink H, Maingon P, Poortmans P, et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol 2015;16:4756.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Romestaing P, Lehingue Y, Carrie C, et al. Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. J Clin Oncol 1997;15:963968.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Polgár C, Fodor J, Orosz Z, et al. Electron and high-dose-rate brachytherapy boost in the conservative treatment of stage I-II breast cancer: first results of the randomized Budapest boost trial. Strahlenther Onkol 2002;178:615623.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Moran MS, Zhao Y, Ma S, et al. Association of radiotherapy boost for ductal carcinoma in situ with local control after whole-breast radiotherapy. JAMA Oncol 2017;3:10601068.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    King MT, Link EK, Whelan TJ, et al. Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial. Lancet Oncol 2020;21:685698.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Chua BH, Link E, Kunkler I, et al. Abstract GS2-04: a randomized phase III study of radiation doses and fractionation schedules in non-low risk ductal carcinoma in situ (DCIS) of the breast (BIG 3-07/TROG 07.01) [abstract]. Cancer Res 2021;81(4_Supplement):GS204.

    • Search Google Scholar
    • Export Citation
  • 35.

    Di Saverio S, Catena F, Santini D, et al. 259 patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up. Breast Cancer Res Treat 2008;109:405416.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Gilleard O, Goodman A, Cooper M, et al. The significance of the Van Nuys prognostic index in the management of ductal carcinoma in situ. World J Surg Oncol 2008;6:61.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 37.

    Silverstein MJ, Lagios MD, Craig PH, et al. A prognostic index for ductal carcinoma in situ of the breast. Cancer 1996;77:22672274.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Silverstein MJ, Lagios MD, Groshen S, et al. The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 1999;340:14551461.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Hughes LL, Wang M, Page DL, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009;27:53195324.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    McCormick B, Winter KA, Woodward W, et al. Randomized phase III trial evaluating radiation following surgical excision for good-risk ductal carcinoma in situ: long-term report from NRG Oncology/RTOG 9804. J Clin Oncol 2021;39:35743582.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Vicini FA, Cecchini RS, White JR, et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet 2019;394:21552164.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Whelan TJ, Julian JA, Berrang TS, et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet 2019;394:21652172.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    Livi L, Meattini I, Marrazzo L, et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer 2015;51:451463.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Strnad V, Ott OJ, Hildebrandt G, et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet 2016;387:229238.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Morrow M, Van Zee KJ, Solin LJ, et al. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. Pract Radiat Oncol 2016;6:287295.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46.

    MacDonald HR, Silverstein MJ, Mabry H, et al. Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins. Am J Surg 2005;190:521525.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47.

    Dunne C, Burke JP, Morrow M, et al. Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol 2009;27:16151620.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48.

    Van Zee KJ, Subhedar P, Olcese C, et al. Relationship between margin width and recurrence of ductal carcinoma in situ: Analysis of 2996 women treated with breast-conserving surgery for 30 years. Ann Surg 2015;262:623631.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    Cody HS III, Van Zee KJ. Point: sentinel lymph node biopsy is indicated for patients with DCIS. J Natl Compr Canc Netw 2003;1:199206.

  • 50.

    Edge SB, Sheldon DG. Counterpoint: sentinel lymph node biopsy is not indicated for ductal carcinoma in situ. J Natl Compr Canc Netw 2003;1:207212.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 51.

    Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005;23:77037720.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 52.

    Virnig BA, Tuttle TM, Shamliyan T, et al. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst 2010;102:170178.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Brennan ME, Turner RM, Ciatto S, et al. Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer. Radiology 2011;260:119128.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97: 16521662.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:13711388.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Tan-Chiu E, Wang J, Costantino JP, et al. Effects of tamoxifen on benign breast disease in women at high risk for breast cancer. J Natl Cancer Inst 2003;95:302307.

  • 57.

    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:16871717.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 58.

    Allred DC, Bryant J, Land S, et al. Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: findings from the NSABP Protocol B-24 [abstract]. Breast Cancer Res Treat 2002;76:S36.

    • Search Google Scholar
    • Export Citation
  • 59.

    DeCensi A, Puntoni M, Guerrieri-Gonzaga A, et al. Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia. J Clin Oncol 2019;37:16291637.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Forbes JF, Sestak I, Howell A, et al. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial [published online December 11, 2015]. Lancet, doi: 10.1016/S0140-6736(15)01129-0

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61.

    Margolese RG, Cecchini RS, Julian TB, et al. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial [published online December 10, 2015]. Lancet, doi: 10.1016/S0140-6736(15)01168-X

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62.

    Louie RJ, Tonneson JE, Gowarty M, et al. Complete blood counts, liver function tests, and chest x-rays as routine screening in early-stage breast cancer: value added or just cost? Breast Cancer Res Treat 2015;154: 99103.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 63.

    Esserman L. Integration of imaging in the management of breast cancer. J Clin Oncol 2005;23:16011602.

  • 64.

    Gundry KR. The application of breast MRI in staging and screening for breast cancer. Oncology (Williston Park) 2005;19:159169; discussion 170, 173–174, 177.

    • Search Google Scholar
    • Export Citation
  • 65.

    Houssami N, Ciatto S, Macaskill P, et al. Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. J Clin Oncol 2008;26:32483258.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 66.

    Weber JJ, Bellin LS, Milbourn DE, et al. Selective preoperative magnetic resonance imaging in women with breast cancer: no reduction in the reoperation rate. Arch Surg 2012;147:834839.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 67.

    Feigelson HS, James TA, Single RM, et al. Factors associated with the frequency of initial total mastectomy: results of a multi-institutional study. J Am Coll Surg 2013;216:966975.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68.

    Katipamula R, Degnim AC, Hoskin T, et al. Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol 2009;27:40824088.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 69.

    Sorbero MES, Dick AW, Beckjord EB, et al. Diagnostic breast magnetic resonance imaging and contralateral prophylactic mastectomy. Ann Surg Oncol 2009;16:15971605.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70.

    Miller BT, Abbott AM, Tuttle TM. The influence of preoperative MRI on breast cancer treatment. Ann Surg Oncol 2012;19:536540.

  • 71.

    Peters NHGM, van Esser S, van den Bosch MAAJ, et al. Preoperative MRI and surgical management in patients with nonpalpable breast cancer: the MONET - randomised controlled trial. Eur J Cancer 2011;47:879886.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 72.

    Turnbull LW, Brown SR, Olivier C, et al. Multicentre randomised controlled trial examining the cost-effectiveness of contrast-enhanced high field magnetic resonance imaging in women with primary breast cancer scheduled for wide local excision (COMICE). Health Technol Assess 2010;14:1182.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 73.

    Fischer U, Zachariae O, Baum F, et al. The influence of preoperative MRI of the breasts on recurrence rate in patients with breast cancer. Eur Radiol 2004;14:17251731.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 74.

    Solin LJ, Orel SG, Hwang WT, et al. Relationship of breast magnetic resonance imaging to outcome after breast-conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ. J Clin Oncol 2008;26:386391.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 75.

    Bleicher RJ, Ciocca RM, Egleston BL, et al. Association of routine pretreatment magnetic resonance imaging with time to surgery, mastectomy rate, and margin status. J Am Coll Surg 2009;209:180187; quiz 294–295.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 76.

    Turnbull L, Brown S, Harvey I, et al. Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial. Lancet 2010;375:563571.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77.

    de Bresser J, de Vos B, van der Ent F, et al. Breast MRI in clinically and mammographically occult breast cancer presenting with an axillary metastasis: a systematic review. Eur J Surg Oncol 2010;36:114119.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 78.

    Morrogh M, Morris EA, Liberman L, et al. MRI identifies otherwise occult disease in select patients with Paget disease of the nipple. J Am Coll Surg 2008;206:316321.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 79.

    Frei KA, Bonel HM, Pelte MF, et al. Paget disease of the breast: findings at magnetic resonance imaging and histopathologic correlation. Invest Radiol 2005;40:363367.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 80.

    Monticciolo DL, Newell MS, Moy L, et al. Breast cancer screening in women at higher-than-average risk: recommendations from the ACR. J Am Coll Radiol 2018;15:408414.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 81.

    White J, Morrow M, Moughan J, et al. Compliance with breast-conservation standards for patients with early-stage breast carcinoma. Cancer 2003;97:893904.

  • 82.

    Wilkinson NW, Shahryarinejad A, Winston JS, et al. Concordance with breast cancer pathology reporting practice guidelines. J Am Coll Surg 2003;196:3843.

  • 83.

    Baucom DH, Porter LS, Kirby JS, et al. Psychosocial issues confronting young women with breast cancer. Breast Dis 2006;23:103113.

  • 84.

    Dunn J, Steginga SK. Young women’s experience of breast cancer: defining young and identifying concerns. Psychooncology 2000;9: 137146.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 85.

    Ganz PA, Greendale GA, Petersen L, et al. Breast cancer in younger women: reproductive and late health effects of treatment. J Clin Oncol 2003;21:41844193.

  • 86.

    Gorman JR, Bailey S, Pierce JP, et al. How do you feel about fertility and parenthood? The voices of young female cancer survivors. J Cancer Surviv 2012;6:200209.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 87.

    Howard-Anderson J, Ganz PA, Bower JE, et al. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst 2012;104: 386405.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 88.

    Kranick JA, Schaefer C, Rowell S, et al. Is pregnancy after breast cancer safe? Breast J 2010;16:404411.

  • 89.

    Sukumvanich P, Case LD, Van Zee K, et al. Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study. Cancer 2010;116:31023111.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 90.

    Quinn GP, Block RG, Clayman ML, et al. If you did not document it, it did not happen: rates of documentation of discussion of infertility risk in adolescent and young adult oncology patients’ medical records. J Oncol Pract 2015;11:137144.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 91.

    Yee S, Abrol K, McDonald M, et al. Addressing oncofertility needs: views of female cancer patients in fertility preservation. J Psychosoc Oncol 2012;30:331346.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 92.

    Yeomanson DJ, Morgan S, Pacey AA. Discussing fertility preservation at the time of cancer diagnosis: dissatisfaction of young females. Pediatr Blood Cancer 2013;60:19962000.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 93.

    Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013;31:25002510.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 94.

    Cruz MRS, Prestes JC, Gimenes DL, et al. Fertility preservation in women with breast cancer undergoing adjuvant chemotherapy: a systematic review. Fertil Steril 2010;94:138143.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 95.

    Dunn L, Fox KR. Techniques for fertility preservation in patients with breast cancer. Curr Opin Obstet Gynecol 2009;21:6873.

  • 96.

    Oktem O, Oktay K. Fertility preservation for breast cancer patients. Semin Reprod Med 2009;27:486492.

  • 97.

    Redig AJ, Brannigan R, Stryker SJ, et al. Incorporating fertility preservation into the care of young oncology patients. Cancer 2011;117:410.

  • 98.

    Lee S, Ozkavukcu S, Heytens E, et al. Value of early referral to fertility preservation in young women with breast cancer. J Clin Oncol 2010;28:46834686.

  • 99.

    Peate M, Meiser B, Friedlander M, et al. It’s now or never: fertility-related knowledge, decision-making preferences, and treatment intentions in young women with breast cancer--an Australian fertility decision aid collaborative group study. J Clin Oncol 2011;29:16701677.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 100.

    Blumenfeld Z, Evron A. Preserving fertility when choosing chemotherapy regimens - the role of gonadotropin-releasing hormone agonists. Expert Opin Pharmacother 2015;16:10091020.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 101.

    Del Mastro L, Lambertini M. Temporary ovarian suppression with gonadotropin-releasing hormone agonist during chemotherapy for fertility preservation: toward the end of the debate? Oncologist 2015;20:12331235.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 102.

    Lambertini M, Peccatori FA, Moore HCF, et al. Reply to the letter to the editor ‘can ovarian suppression with gonadotropin releasing hormone analogs (GnRHa) preserve fertility in cancer patients?’ by Rodriguez-Wallberg et al [published online December 8, 2015]. Ann Oncol, doi: 10.1093/annonc/mdv599

    • Search Google Scholar
    • Export Citation
  • 103.

    Moore HCF, Unger JM, Phillips KA, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 2015;372:923932.

  • 104.

    Moffat R, Güth U. Preserving fertility in patients undergoing treatment for breast cancer: current perspectives. Breast Cancer (Dove Med Press) 2014;6:93101.

    • Search Google Scholar
    • Export Citation
  • 105.

    Oktay K, Turan V, Bedoschi G, et al. Fertility preservation success subsequent to concurrent aromatase inhibitor treatment and ovarian stimulation in women with breast cancer. J Clin Oncol 2015;33:24242429.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 106.

    Ravaioli A, Pasini G, Polselli A, et al. Staging of breast cancer: new recommended standard procedure. Breast Cancer Res Treat 2002;72:5360.

  • 107.

    Puglisi F, Follador A, Minisini AM, et al. Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications. Ann Oncol 2005;16:263266.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 108.

    Brothers JM, Kidwell KM, Brown RKJ, et al. Incidental radiologic findings at breast cancer diagnosis and likelihood of disease recurrence. Breast Cancer Res Treat 2016;155:395403.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 109.

    Kumar R, Chauhan A, Zhuang H, et al. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat 2006;98:267274.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 110.

    Podoloff DA, Advani RH, Allred C, et al. NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw 2007; 5(S1):S122; quiz S23–24.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 111.

    Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. Radiographics 2007;27(Suppl 1):S215229.

  • 112.

    Wahl RL, Siegel BA, Coleman RE, et al. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group. J Clin Oncol 2004;22:277285.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 113.

    Arriagada R, MG, Rochard F, et al. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group. J Clin Oncol 1996;14:15581564.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 114.

    Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:20872106.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 115.

    Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002;347:12331241.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 116.

    Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002;347:12271232.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 117.

    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011;378:17071716.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 118.

    Fourquet A, Campana F, Zafrani B, et al. Prognostic factors of breast recurrence in the conservative management of early breast cancer: a 25-year follow-up. Int J Radiat Oncol Biol Phys 1989;17:719725.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 119.

    Komoike Y, Akiyama F, Iino Y, et al. Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases. Cancer 2006;106:3541.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 120.

    Zhou P, Gautam S, Recht A. Factors affecting outcome for young women with early stage invasive breast cancer treated with breast-conserving therapy. Breast Cancer Res Treat 2007;101:5157.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 121.

    Golshan M, Miron A, Nixon AJ, et al. The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy. Am J Surg 2006;192: 5862.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 122.

    Kroman N, Holtveg H, Wohlfahrt J, et al. Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma. Cancer 2004;100:688693.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 123.

    Blichert-Toft M, Nielsen M, Düring M, et al. Long-term results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol. Acta Oncol 2008;47:672681.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 124.

    Litière S, Werutsky G, Fentiman IS, et al. Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol 2012;13: 412419.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 125.

    Agarwal S, Pappas L, Neumayer L, et al. Effect of breast conservation therapy vs mastectomy on disease-specific survival for early-stage breast cancer. JAMA Surg 2014;149:267274.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 126.

    Hwang ES, Lichtensztajn DY, Gomez SL, et al. Survival after lumpectomy and mastectomy for early stage invasive breast cancer: the effect of age and hormone receptor status. Cancer 2013;119:14021411.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 127.

    Hartmann-Johnsen OJ, Kåresen R, Schlichting E, et al. Survival is better after breast conserving therapy than mastectomy for early stage breast cancer: a registry-based follow-up study of Norwegian women primary operated between 1998 and 2008. Ann Surg Oncol 2015;22: 38363845.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 128.

    Chatterjee A, Pyfer B, Czerniecki B, et al. Early postoperative outcomes in lumpectomy versus simple mastectomy. J Surg Res 2015;198: 143148.

  • 129.

    Recht A. Contralateral prophylactic mastectomy: caveat emptor. J Clin Oncol 2009;27:13471349.

  • 130.

    Bedrosian I, Hu CY, Chang GJ. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst 2010;102:401409.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 131.

    Jatoi I, Parsons HM. Contralateral prophylactic mastectomy and its association with reduced mortality: evidence for selection bias. Breast Cancer Res Treat 2014;148:389396.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 132.

    Portschy PR, Kuntz KM, Tuttle TM. Survival outcomes after contralateral prophylactic mastectomy: a decision analysis. J Natl Cancer Inst 2014;106:dju106.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 133.

    Fayanju OM, Stoll CRT, Fowler S, et al. Contralateral prophylactic mastectomy after unilateral breast cancer: a systematic review and meta-analysis. Ann Surg 2014;260:10001010.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 134.

    Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol 2014;32: 15071515.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 135.

    Axelsson CK, Mouridsen HT, Zedeler K, et al. Axillary dissection of level I and II lymph nodes is important in breast cancer classification. Eur J Cancer 1992;28:14151418.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 136.

    Kiricuta CI, Tausch J. A mathematical model of axillary lymph node involvement based on 1446 complete axillary dissections in patients with breast carcinoma. Cancer 1992;69:24962501.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 137.

    Bland KI, Scott-Conner CE, Menck H, et al. Axillary dissection in breast-conserving surgery for stage I and II breast cancer: a National Cancer Data Base study of patterns of omission and implications for survival. J Am Coll Surg 1999;188:586595; discussion 595–596.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 138.

    Deutsch M, Land S, Begovic M, et al. The incidence of arm edema in women with breast cancer randomized on the National Surgical Adjuvant Breast and Bowel Project study B-04 to radical mastectomy versus total mastectomy and radiotherapy versus total mastectomy alone. Int J Radiat Oncol Biol Phys 2008;70:10201024.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 139.

    Fleissig A, Fallowfield LJ, Langridge CI, et al. Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat 2006;95:279293.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 140.

    Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol 2007;25:36573663.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 141.

    Giuliano AE, Hawes D, Ballman KV, et al. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA 2011;306:385393.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 142.

    Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003;349:546553.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 143.

    Veronesi U, Paganelli G, Viale G, et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol 2006;7:983990.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 144.

    Krag DN, Julian TB, Harlow SP, et al. NSABP-32: phase III, randomized trial comparing axillary resection with sentinal lymph node dissection: a description of the trial. Ann Surg Oncol 2004; 11(3 Suppl)208S210S.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 145.

    Land SR, Kopec JA, Julian TB, et al. Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32. J Clin Oncol 2010;28: 39293936.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 146.

    Ashikaga T, Krag DN, Land SR, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol 2010;102:111118.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 147.

    Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 2006;98: 599609.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 148.

    Gill G, SNAC Trial Group of the Royal Australasian College of Surgeons (RACS) and NHMRC Clinical Trials Centre. Sentinel-lymph-node-based management or routine axillary clearance? One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): a randomized controlled surgical trial. Ann Surg Oncol 2009;16:266275.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 149.

    Husted Madsen A, Haugaard K, Soerensen J, et al. Arm morbidity following sentinel lymph node biopsy or axillary lymph node dissection: a study from the Danish Breast Cancer Cooperative Group. Breast 2008;17:138147.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 150.

    Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 2010;252:426432; discussion 432 – 433.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 151.

    Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011;305:569575.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 152.

    Giuliano AE, Ballman K, McCall L, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 randomized trial. Ann Surg 2016;264:413420.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 153.

    Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 2013;14:297305.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 154.

    Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 2014;15:13031310.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 155.

    Rutgers E, Donker M, Poncet C, et al. Abstract GS4-01: Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: 10 year follow up results of the EORTC AMAROS trial (EORTC 10981/22023) [abstract]. Cancer Res 2019;79(4 Suppl):GS401.

    • Search Google Scholar
    • Export Citation
  • 156.

    Sávolt Á, Péley G, Polgár C, et al. Eight-year follow up result of the OTOASOR trial: the optimal treatment of the axilla - surgery or radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: a randomized, single centre, phase III, non-inferiority trial. Eur J Surg Oncol 2017;43:672679.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 157.

    Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 2013;14:609618.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 158.

    Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 2013;310:14551461.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 159.

    Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol 2015;33:258264.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 160.

    Boughey JC, Ballman KV, Le-Petross HT, et al. Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0-T4, N1-N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (Alliance). Ann Surg 2016;263:802807.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 161.

    Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol 2016;34:10721078.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 162.

    Edge SB, Byrd DR, Compton CC, et al. eds. American Joint Committee on Cancer (AJCC) Cancer Staging Manual. 7th ed. New York, NY: Springer Science+Business Media, LLC; 2010.

    • Search Google Scholar
    • Export Citation
  • 163.

    Rocha RD, Girardi AR, Pinto RR, et al. Axillary ultrasound and fine-needle aspiration in preoperative staging of axillary lymph nodes in patients with invasive breast cancer. Radiol Bras 2015;48:345352.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 164.

    Mulliez T, Veldeman L, van Greveling A, et al. Hypofractionated whole breast irradiation for patients with large breasts: a randomized trial comparing prone and supine positions. Radiother Oncol 2013;108:203208.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 165.

    Antonini N, Jones H, Horiot JC, et al. Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882. Radiother Oncol 2007;82:265271.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 166.

    Bartelink H, Horiot JC, Poortmans P, et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 2001;345:13781387.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 167.

    Pignol JP, Olivotto I, Rakovitch E, et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol 2008;26:20852092.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 168.

    Mukesh MB, Barnett GC, Wilkinson JS, et al. Randomized controlled trial of intensity-modulated radiotherapy for early breast cancer: 5-year results confirm superior overall cosmesis. J Clin Oncol 2013;31: 44884495.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 169.

    The START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 2008;371:10981107.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 170.

    The START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 2008;9:331341.

    • Search Google Scholar
    • Export Citation
  • 171.

    Owen JR, Ashton A, Bliss JM, et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol 2006;7:467471.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 172.

    Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010;362:513520.

  • 173.

    Haviland JS, Owen JR, Dewar JA, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 2013;14:10861094.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 174.

    Offersen BV, Alsner J, Nielsen HM, et al. Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomized phase III trial: the DBCG HYPO Trial. J Clin Oncol 2020;38:36153625.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 175.

    Brunt AM, Haviland JS, Sydenham M, et al. Ten-year results of FAST: a randomized controlled trial of 5-fraction whole-breast radiotherapy for early breast cancer. J Clin Oncol 2020;38:32613272.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 176.

    Murray Brunt A, Haviland JS, Wheatley DA, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet 2020;395:16131626.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 177.

    Vrieling C, Collette L, Fourquet A, et al. The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC ‘boost vs. no boost’ trial. Radiother Oncol 2000;55:219232.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 178.

    Jones HA, Antonini N, Hart AAM, et al. Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. J Clin Oncol 2009;27:49394947.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 179.

    Vrieling C, van Werkhoven E, Maingon P, et al. Prognostic factors for local control in breast cancer after long-term follow-up in the EORTC boost vs no boost trial: a randomized clinical trial. JAMA Oncol 2017;3:4248.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 180.

    Frazier RC, Kestin LL, Kini V, et al. Impact of boost technique on outcome in early-stage breast cancer patients treated with breast-conserving therapy. Am J Clin Oncol 2001;24:2632.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 181.

    Whelan TJ, Olivotto IA, Parulekar WR, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med 2015;373:307316.

  • 182.

    Poortmans PM, Collette S, Kirkove C, et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med 2015;373:317327.

  • 183.

    Poortmans PM, Weltens C, Fortpied C, et al. Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial. Lancet Oncol 2020;21:16021610.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 184.

    Gentile MS, Usman AA, Neuschler EI, et al. contouring guidelines for the axillary lymph nodes for the delivery of radiation therapy in breast cancer: evaluation of the RTOG Breast Cancer Atlas. Int J Radiat Oncol Biol Phys 2015;93:257265.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 185.

    Offersen BV, Boersma LJ, Kirkove C, et al. ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer, version 1.1. Radiother Oncol 2016;118:205208.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 186.

    Coles CE, Griffin CL, Kirby AM, et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet 2017;390:10481060.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 187.

    Meattini I, Marrazzo L, Saieva C, et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial. J Clin Oncol 2020;38:41754183.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 188.

    Polgár C, Major T, Takácsi-Nagy Z, et al. Breast-conserving surgery followed by partial or whole breast irradiation: twenty-year results of a phase 3 clinical study. Int J Radiat Oncol Biol Phys 2021;109:9981006.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 189.

    Bhattacharya IS, Haviland JS, Kirby AM, et al. Patient-reported outcomes over 5 years after whole- or partial-breast radiotherapy: longitudinal analysis of the IMPORT LOW (CRUK/06/003) phase III randomized controlled trial. J Clin Oncol 2019;37:305317.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 190.

    Olivotto IA, Whelan TJ, Parpia S, et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. J Clin Oncol 2013;31:40384045.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 191.

    Correa C, Harris EE, Leonardi MC, et al. Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement. Pract Radiat Oncol 2017;7:7379.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 192.

    Kim YB, Byun HK, Kim DY, et al. effect of elective internal mammary node irradiation on disease-free survival in women with node-positive breast cancer: a randomized phase 3 clinical trial. JAMA Oncol 2022;8:96105.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 193.

    Thorsen LBJ, Overgaard J, Matthiessen LW, et al. Internal mammary node irradiation in patients with node-positive early breast cancer: fifteen-year results from the Danish Breast Cancer Group internal mammary node study [published online April 8, 2022]. J Clin Oncol, doi: 10.1200/JCO.22.00044

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 194.

    Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 2004;351:971977.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 195.

    Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol 2013;31:23822387.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 196.

    Fyles AW, McCready DR, Manchul LA, et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med 2004;351:963970.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 197.

    Kunkler IH, Williams LJ, Jack WJL, et al. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol 2015;16:266273.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 198.

    Hellman S. Stopping metastases at their source. N Engl J Med 1997;337:996997.

  • 199.

    Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997;337:949955.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 200.

    Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999;353:16411648.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 201.

    Ragaz J, Olivotto IA, Spinelli JJ, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 2005;97:116126.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 202.

    Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:15391569.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 203.

    EBCTCG (Early Breast Cancer Trialists’ Collaborative Group). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 2014;383:21272135.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 204.

    Nielsen HM, Overgaard M, Grau C, et al. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol 2006;24:22682275.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 205.

    Abdel-Wahab M, Wolfson A, Raub W, et al. The importance of postoperative radiation therapy in multimodality management of locally advanced breast cancer: a phase II trial of neoadjuvant MVAC, surgery, and radiation. Int J Radiat Oncol Biol Phys 1998;40:875880.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 206.

    Huang EH, Tucker SL, Strom EA, et al. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol 2004;22:46914699.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 207.

    McGuire SE, Gonzalez-Angulo AM, Huang EH, et al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys 2007;68:10041009.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 208.

    Swisher SK, Vila J, Tucker SL, et al. Locoregional control according to breast cancer subtype and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast-conserving therapy. Ann Surg Oncol 2016;23:749756.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 209.

    Bellon JR, Come SE, Gelman RS, et al. Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial. J Clin Oncol 2005;23:19341940.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 210.

    Recht A, Come SE, Henderson IC, et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med 1996;334:13561361.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 211.

    Pierce LJ, Hutchins LF, Green SR, et al. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. J Clin Oncol 2005;23:2429.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 212.

    Harris EER, Christensen VJ, Hwang WT, et al. Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment. J Clin Oncol 2005;23:1116.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 213.

    Ahn PH, Vu HT, Lannin D, et al. Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. J Clin Oncol 2005;23:1723.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 214.

    Li YF, Chang L, Li WH, et al. Radiotherapy concurrent versus sequential with endocrine therapy in breast cancer: a meta-analysis. Breast 2016;27:9398.

  • 215.

    Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 2017;376: 21472159.

  • 216.

    Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med 2021;384:23942405.

  • 217.

    Mignot F, Ajgal Z, Xu H, et al. Concurrent administration of anti-HER2 therapy and radiotherapy: systematic review. Radiother Oncol 2017;124:190199.